 Akari Therapeutics, Plc AKTX, a biopharmaceutical company focused on innovative therapeutics to treat orphan autoimmune and inflammatory diseases where the complement andor leukotriene systems are implicated, announces that a U.S. Food and Drug Administration FDA investigational new drug application IND is open for its multicenter Phase III study for the treatment of pediatric HSCT-TMA with nomacopan, allowing clinical sites to open in the first quarter of 2020. 